Cancer
Neuroblastoma
神经母细胞瘤
A childhood tumour arising from immature cells of the sympathetic nervous system.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 352
- cities
- 81
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 27% of the world's English-language research papers on neuroblastoma, 2021–2025 (18% in 2016–2020), and 6% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
352 hospitals in 81 cities
Order: papers led on neuroblastoma, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 1 papers or 1 trial on neuroblastoma, or was a site in 1 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens neuroblastoma in that city. 71 more cities are in the menu below.
- 49 papers ledNo open trial led
- 47 papers ledNo open trial led
- 33 papers led
- 32 papers led
- 21 papers led
- 17 papers ledNo open trial led
- 16 papers ledNo open trial led
- 15 papers led
- 15 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers led
- 7 papers led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 52
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 100 papers led6 hospitals
- 55 papers led5 hospitals
- 49 papers led6 hospitals
- 35 papers led4 hospitals
- 30 papers led6 hospitals
- 30 papers led5 hospitals
- 23 papers led4 hospitals
- 22 papers led5 hospitals
- 22 papers led1 hospital
- 20 papers led5 hospitals
- 19 papers led4 hospitals
- 18 papers led4 hospitals
- 17 papers led2 hospitals
- 16 papers led4 hospitals
- 16 papers led4 hospitals
- 15 papers led6 hospitals
- 14 papers led3 hospitals
- 13 papers led5 hospitals
- 11 papers led1 hospital
- 11 papers led2 hospitals
- 11 papers led3 hospitals
- 11 papers led5 hospitals
- 10 papers led1 hospital
- 10 papers led5 hospitals
- 10 papers led4 hospitals
- 9 papers led3 hospitals
- 9 papers led3 hospitals
- 8 papers led2 hospitals
- 7 papers led4 hospitals
- 7 papers led4 hospitals
- 7 papers led5 hospitals
- 6 papers led3 hospitals
- 6 papers led3 hospitals
- 6 papers led5 hospitals
- 5 papers led1 hospital
- 5 papers led4 hospitals
- 4 papers led3 hospitals
- 4 papers led1 hospital
- 4 papers led2 hospitals
- 4 papers led1 hospital
- 4 papers led3 hospitals
- 3 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 1 paper led1 hospital
- 1 paper led0 hospitals
- 1 paper led1 hospital
- 0 papers led0 hospitals
open trials on neuroblastoma in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 13 Nov 2026, with at least one listed hospital as lead sponsor or site, and at least one listed hospital's site marked open. 17 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingPhase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07318831
Age 0 years to 18 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07502287
Age 12 months to 21 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingPhase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07584499
Age 2 years to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSafety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
- Phase
- Early phase 1
- Started
- 2026-07
- Registry
- NCT07767630
Age 1 year to 100 years (registered criteria)
Led by West China HospitalChengdu
- Recruiting18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06852807
Age Not stated to 18 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingArsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06933394
Age 18 months to 18 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingSafety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07067346
Age 12 months to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingEfficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06255210
Age 18 years to Not stated (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
- RecruitingAdding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06574698
Age 1 year to 21 years (registered criteria)
Led by Guangzhou Women and Children's Medical CenterGuangzhou
- RecruitingPhase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06631391
Age 1 day to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingChimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06751134
Age 1 year to 12 years (registered criteria)
Led by Children's Hospital of Nanjing Medical UniversityNanjing
- RecruitingHetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06818916
Age Not stated to 18 years (registered criteria)
Led by Beijing Children's HospitalBeijing
- RecruitingSafety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Registry
- NCT06836505
Age 1 year to 50 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteDongguan, Guangzhou
- RecruitingClinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07195500
Age 6 months to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingAPG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05701306
Age 5 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Wuhan
- RecruitingClinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT06013618
Age 12 months to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
- Phase
- Phase 1
- Started
- 2022-12
- Registry
- NCT05562024
Age 1 year to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesJinan, Tianjin
- RecruitingClinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT07064746
Age Not stated to 18 years (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingSerial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
- Phase
- Not given
- Started
- 2022-01
- Registry
- NCT07516678
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Recruiting18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
- Phase
- Early phase 1
- Started
- 2021-09
- Registry
- NCT05069220
Age 1 year to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 13 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.